SCHEMBL5117466

SCHEMBL5117466

Fc1ccc(-c2cccc(N(c3ccccc3)c3cccc(-c4ccc(F)cc4F)n3)n2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 2/20 0.43
▸ AGER Q15109 2/20 0.39
▸ CTSA P10619 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ MDM2 Q00987 1/20 0.38
▸ ADORA1 P30542 3/20 0.37
▸ ADORA2A P29274 2/20 0.37
▸ HSD17B14 Q9BPX1 1/20 0.37
▸ SCN9A Q15858 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ GRM5 P41594 1/20 0.36
▸ FABP4 P15090 1/20 0.36
▸ FABP5 Q01469 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ SENP8 Q96LD8 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923248 0.84 SCN9A (0.40) KMOAGERHSD17B14SCN9ANPC1
SCHEMBL13261826 0.79 KMO (0.51) KMOAGERCTSATP53MDM2
SCHEMBL19072692 0.74 KMO (0.47) KMOAGERCTSATP53MDM2
SCHEMBL5109003 0.73 TDP1 (0.42) TP53MEN1NPC1RAB9AKMT2A
SCHEMBL14556440 0.72 KMO (0.36) KMOCTSATP53MDM2ADORA1
SCHEMBL5115896 0.72 MEN1 (0.58) TP53ADORA1ADORA2AMEN1NPC1
SCHEMBL9106265 0.71 KMO (0.45) KMOAGERCTSATP53MDM2
SCHEMBL3923995 0.71 KMO (0.45) KMOAGERADORA1ADORA2ASCN9A
SCHEMBL15888380 0.71 CCR1 (0.52) KMOAGERCTSASCN9AGRM5
SCHEMBL9277799 0.71 KDM4E (0.58) KMOTP53MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1683804-B1 PLATINUM COMPLEX AND LUMINESCENT ELEMENT TAKASAGO PERFUMERY CO LTD (JP) 2013-07-31 — — EP disclosed
EP-1683804-B1 PLATINUM COMPLEX AND LUMINESCENT ELEMENT TAKASAGO PERFUMERY CO LTD (JP) 2013-07-31 — — EP disclosed
US-7442797-B2 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-10-28 — — US disclosed
US-7442797-B2 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-10-28 — — US disclosed
US-7442797-B2 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-10-28 — — US disclosed
US-20080079358-A1 Organic electroluminescent element FUJIFILM CORPORATION 2008-04-03 — — US disclosed
US-20080079358-A1 Organic electroluminescent element FUJIFILM CORPORATION 2008-04-03 — — US disclosed
US-20070103060-A1 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-05-10 — — US disclosed
US-20070103060-A1 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-05-10 — — US disclosed
US-20070103060-A1 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-05-10 — — US disclosed
EP-1683804-A2 PLATINUM COMPLEX AND LUMINESCENT ELEMENT Takasago International Corporation (JP) 2006-07-26 — — EP disclosed
US-20060134461-A1 Organometallic materials and electroluminescent devices EASTMAN KODAK COMPANY 2006-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070103060-A1 Platinum complex and light emitting device UBE2D3, PCID2, CCND2 KMO 2746/4885AGER 4681/4885CTSA 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback